|Year : 2014 | Volume
| Issue : 2 | Page : 48-53
Antidepressant-like effect of resveratrol in a subchronic model of depression
Rania F Ahmed1, Rehab F Abdel-Rahman1, Heba Abdallah1, Dalia O Saleh1, Omar A. H. A Farid2, Alyaa F Hessin1
1 Department of Pharmacology, National Research Centre, Giza, Egypt
2 Department of Physiology, National Organization for Drug Control and Research, Giza, Egypt
|Date of Submission||04-May-2014|
|Date of Acceptance||17-Jun-2014|
|Date of Web Publication||28-Nov-2014|
Rania F Ahmed
Department of Pharmacology, National Research Centre, El-Bohoth St., Dokki, PO Box 12311, Cairo
Source of Support: None, Conflict of Interest: None
Background and aim
Depression is one of the most serious and common mental diseases with major negative social consequences. Transresveratrol (trans-3,5,4΄-trihydroxystilbene) is a polyphenolic compound with a broad spectrum of pharmacological activities. It has been detected in some fruits and herbs, including the Asian plant Polygonum cuspidatum. The aim of this study was to assess the antidepressant-like effect of transresveratrol in a reserpine subchronic model of depression.
Materials and methods
Depression-like behaviours were induced in rats by reserpine injection (0.25 mg/kg, subcutaneously) every 48 h, for 20 days. Transresveratrol (60 and 120 mg/kg) and fluoxetine (10 mg/kg) were administered orally daily during the 20 days of the study. Behavioural tests, namely, open-field test and forced swimming test, as well as brain neurotransmitters levels and antioxidant contents and liver functions, were assessed.
Data revealed that transresveratrol improved the rats' behaviour in both the open-field test and forced swimming test, and also elevated the brain's neurotransmitter content, normalized the liver enzymes level, and improved the antioxidant status of both the brain and liver, compared with those of fluoxetine.
The present study provided a clear evidence for the antidepressant-like of transresveratrol in the experimental model of depression. Further investigations are required to investigate the mechanism of action of transresveratrol as well as its applicability to be used as an antidepressant.
Keywords: behaviour, depression, neurotransmitters, Polygonum cuspidatum, transresveratol
|How to cite this article:|
Ahmed RF, Abdel-Rahman RF, Abdallah H, Saleh DO, Farid OA, Hessin AF. Antidepressant-like effect of resveratrol in a subchronic model of depression. J Arab Soc Med Res 2014;9:48-53
|How to cite this URL:|
Ahmed RF, Abdel-Rahman RF, Abdallah H, Saleh DO, Farid OA, Hessin AF. Antidepressant-like effect of resveratrol in a subchronic model of depression. J Arab Soc Med Res [serial online] 2014 [cited 2020 May 31];9:48-53. Available from: http://www.new.asmr.eg.net/text.asp?2014/9/2/48/145619
| Introduction|| |
Depression is a prevalent psychiatric disease affecting the quality of life of many people. On the basis of the latest available data from the WHO, depression is expected to become the second leading cause of disease-related disability by the year 2020 . It is one of the top 10 causes of morbidity and mortality worldwide, and despite the exponential increase in the number of antidepressants over the years, the prevalence of the disorder remains the same, which could be because of the unclear pathophysiology. Multiple pathogenic factors are involved in depression; although there are several molecular targets available for the development of new antidepressant drugs, most of the current treatments for depression directly or indirectly affect the monoaminergic system [2,3]. Many synthetic antidepressant drugs show low response rates and even produce adverse side effects such as cardiotoxicity, hypertensive crisis, sexual dysfunction and sleep disorders in depressed patients. Moreover, 15% of the depressed patients are resistant to all known therapies . Therefore, it is desirable to seek antidepressants in natural products; such materials are expected to show fewer side effects [5,6].
Transresveratrol (trans-3, 5, 4-trihydroxystilbene) is a natural polyphenolic compound belonging to the family of phytoalexins, which are low molecular weight secondary metabolites produced by plants for defense against stresses such as wounding, pathogen attack and UV irradiation. It was first isolated from the roots of white hellebore (Veratrum grandiflorum O. Loes) in 1940 and later, in 1963, from the roots of Polygonum cuspidatum, a plant used in traditional Chinese and Japanese medicine. It is also found in grapes, red wine, a variety of berries and peanuts, and is regarded as the main factor in the French paradox, which is the observation that French people suffer a relatively low incidence of coronary heart disease, despite having a diet rich in saturated fats. Therefore, it has received considerable attention owing to its beneficial effects on human health, such as protective effects against inflammation, hepatic injuries, carcinogenesis, oxidation, aging, diabetes and neurodegenerative diseases [7-11].
Fluoxetine is an antidepressant drug of the selective serotonin reuptake inhibitor class, which is commonly prescribed to treat depression . However, it has recently been postulated to induce liver damage and mediates free radical reactions owing to its fluorine content .
The present study was conducted to assess the antidepressant and hepatoprotective effects of transresveratrol in comparison with fluoxetine in an experimental subchronic reserpine model of depression.
| Materials and methods|| |
Animals used were adult male Wister rats, weighing 130-150 g each, purchased from the Animal House at the National Research Centre, Giza, Egypt. All animals received human care in compliance with the guidelines of the animal care and use committee of the NRC. Upon arrival, the animals were kept in a quiet place, housed eight per cage, and acclimatized to a colony room with controlled ambient temperature (22 ± 1°C), humidity (50 ± 10%) and a 12 h natural light/dark cycle. They were fed a standard diet, water was provided ad libitum, and they were acclimated for 7 days before entry into the subsequent study. They were allowed free access to water and food throughout the period of investigation. The experiments were conducted on 16 rats per treatment group according to a randomized schedule. In behavioural tests, animals in every group were intermixed during the observation and the observers were unaware of the treatment conditions. All experiments were conducted according to the National Regulations on Animal Welfare and National Research Centre-Medical Research Ethics Committee for the use of Human or Animal Subjects.
Drugs used were fluoxetine hydrochloride (Prozac 20 mg dispersible tablets; Lilly, Alcobendas, Spain). The tablets were freshly suspended in distilled water before oral administration and transresveratrol that was provided as a generous gift from Jing Tea LLC (Sidney, Australia); it was provided as Harmoni-T micronized transresveratrol capsules for ingestion. The powder in the capsules was freshly dissolved in distilled water just before oral administration. Reserpine was a generous gift from Novartis Co. (Cairo, Egypt): it was provided as pure powder for injection and it was freshly dissolved in a dimethyl sulfoxide (DMSO)/saline mixture (0.1 : 10 ml) before subcutaneous injection.
Rats were divided into five different groups (16 rats each) and were treated as follows: group 1, normal control (DMSO/saline group); group 2, depressed group (reserpine group); group 3, received fluoxetine (10 mg/kg orally) ; and groups 4 and 5 received transresveratrol (60 and 120 mg/kg orally, respectively).
Groups 2, 3, 4 and 5 received reserpine (0.25 mg/kg subcutaneously) every 48 h, for 20 days to induce depression-like symptoms . Group 1 received DMSO/saline every 48 h, for 20 days. Group 1 was kept in separate cages and had free access to food and water till the end of the experiment. Group 2 received only the reserpine with no treatments. All other groups received the corresponding drugs daily starting from day 1 to day 20. On day 21, eight rats were chosen from each group randomly to perform the behavioural tests, namely, open-field test (OFT) and forced swimming test (FST). After 24 h, eight rats from each group were chosen randomly and killed by decapitation. Their brain and liver tissues were isolated, and the tissues were washed with cold sterile physiological saline, blotted between two damp filter papers and stored at -80°C until use for biochemical analyses. Lipid peroxide levels [measured as malondialdehyde (MDA) and reduced glutathione (GSH)] were taken as in-vivo reliable indices for the contribution of free radical generation in oxidative stress. Blood samples were collected from the other eight rats in each group using the retro-orbital veinous plexus and were used in measuring aspartate aminotransferase (AST) and alanine aminotransferase (ALT).
Behavioural tests included the OFT and the FST. The OFT was carried out in a square wooden arena (80 80 40 cm high) with red walls and white smooth polished floor divided by black lines into 16 equal squares. The test was conducted under white light in a quiet room. Each rat was placed at the same corner square and observed during 5 min. The floor and walls were cleaned after testing each rat. The following parameters were recorded during the 5 min observation period: latency: time taken by each animal till it starts moving in the arena; ambulation frequency: number of squares crossed by the animal; rearing frequency: number of times the animal stood stretched on its hind limbs with or without forelimb support; and grooming frequency: the number of face scratching and washing with the hind limbs and licking of the forelimbs [16-19].
The FST was conducted according to the method described by Porsolt et al. . Each rat was placed for 5 min in a cylindrical water tank (70 cm high, 40 cm diameter), where the water level was about 40 cm and water temperature was maintained at 23-25°C. The total duration of immobility of each animal was recorded. The tank was emptied and washed with fresh water flush between each rat to remove any traces of urine or faeces.
Biochemical analyses included the determination of brain monoamine levels and the determination of brain and liver MDA and GSH levels. Each brain tissue was weighed individually and divided into two longitudinal halves, of which one half was homogenized in 75% aqueous high-performance liquid chromatography grade methanol (10% w/v). The homogenate was spun at 4000 rpm for 10 min and the supernatant was isolated. Brain monoamines were detected by high-performance liquid chromatography according to a method described by Pagel et al. . The other half was homogenized in ice-cold saline (20% w/v); each liver tissue was also isolated and homogenized in ice-cold saline (20% w/v). The brain and liver homogenates were divided into two portions for the determination of MDA and GSH levels. The level of MDA was determined according to the method of Ruiz-Larea et al. . The level of GSH was determined according to the method of Ellman  modified by Bulaj et al. .
Serum activities of AST and ALT were estimated according to Reitman and Frankel .
Statistical analyses was carried out by nonparametric K-independent samples Kruskal-Wallis H-test, followed by two independent samples Mann-Whitney U-test in case of ambulation, rearing and grooming frequencies in the OFT, and one-way analysis of variance followed by the least significant difference post-hoc multiple comparisons test to calculate significance in the neurotransmitters levels. For all the other parameters, statistical analyses were carried out using one-way analysis of variance, followed by Tukey's HSD post-hoc multiple comparisons test. Data were expressed as mean ± SEM. Significances were expressed at a P value less than 0.05.
| Results|| |
The results of the OFT are represented in [Figure 1] and [Figure 2]. Depression-like behaviour induced by reserpine could be clearly demonstrated by the significant decrease in the activity of all rats compared with vehicle control values. Transresveratrol (60 and 120 mg/kg, orally) increased the rats' activity significantly compared with the depressed control. Fluoxetine (10 mg/kg, orally) treatment retrieved the normal levels of the open-field parameters.
[Figure 3] showed the effects of transresveratrol (60 and 120 mg/kg, orally) and fluoxetine (10 mg/kg, orally) on the duration of immobility in the FST. Post-hoc analysis revealed that transresveratrol, at a dose of 60 mg/kg, and the classic antidepressant fluoxetine (10 mg/kg, orally), normalized the immobility time. On the contrary, although transresveratrol (120 mg/kg, orally) showed a significant reduction in the immobility duration compared with the depressed control, it is worth mentioning that it recorded higher immobility duration than the lower dose of transresveratrol.
|Figure 1: Effect of transresveratrol on the latency time in the OFT in depressed rats usin g the subchronic reserpine injection model of depression. *Significant from depressed control at P < 0.05. #Signifi cant from normal control at P < 0.05. OFT, open-fi eld test.|
Click here to view
|Figure 2: Effect of transresveratrol on the ambulation, rearing and grooming frequencies in the OFT in depressed rats using the subchronicreserpine injection model of depression. *Signifi cant from depressed|
control at P < 0.05. #Signifi cant from normal control at P < 0.05. OFT, open-fi eld test.
Click here to view
|Figure 3: Effect of transresveratrol on the immobility duration in the forced swimming test in depressed rats using the subchronic reserpine injection model of depression. *Signifi cant from depressed control at P < 0.05. #Signifi cant from normal control at P < 0.05.|
Click here to view
The levels of monoamines detected are summarized in [Figure 4]. Statistics revealed that serotonin, norepinephrine and dopamine levels were decreased significantly compared with the normal levels after reserpine injection. Oral administration of fluoxetine (10 mg/kg) and the two-dose levels of transresveratrol restored the normal values of the three neurotransmitters.
|Figure 4: Effect of transresveratrol on the neurotransmitters levels in depressed rats using the subchronic reserpine injection model of depression. *Signifi cant from depressed control at P < 0.05. #Signifi cant from normal control at P < 0.05.|
Click here to view
[Table 1] shows that chronic administration of reserpine significantly decreased liver GSH content and increased liver MDA level as compared with the normal control group. Treatment of animals with transresveratrol at two-dose levels normalized the liver GSH and MDA levels. Fluoxetine normalized MDA level and significantly increased GSH level compared with the depressed control. Moreover, the obtained data showed that there was no significant difference in the brain contents of GSH and MDA between the normal and the depressed control groups.
|Table 1 Effect of transresveratrol on the brain and liver antioxidant parameter levels in depressed rats using the subchronic reserpine injection model of depression|
Click here to view
[Table 2] shows that chronic administration of reserpine significantly increased serum levels of ALT and AST as compared with the normal control group. Treatment of animals with fluoxetine and resveratrol at two-dose levels significantly decreased liver enzyme levels as compared with depressed control values. The hepatotoxicity indices (ALT and AST) reached 81.8 and 85.1% for fluoxetine (10 mg/kg), 74.1 and 85.8% for resveratrol (60 mg/kg body weight), and 70.3 and 84.2% for resveratrol (120 mg/kg body weight), respectively, as compared with the depressed control group. It is noteworthy that the higher dose of resveratrol (120 mg/kg body weight) showed better protection against increased serum level of ALT than fluoxetine.
|Table 2 Effect of transresveratrol on the serum ALT and AST levels in depressed rats using the subchronic reserpine injection model of depression|
Click here to view
| Discussion|| |
This study was planned to investigate the antidepressant and hepatoprotective effects of transresveratrol against fluoxetine in a subchronic reserpine model of depression. Reserpine, a well-known antihypertensive drug, is also famous for inducing depression in patients being treated for hypertension, as well as in normal subjects, owing to its capability to pass the blood-brain barrier and depleting the peripheral monoamine stores, which account for much of the beneficial antihypertensive effect used over the years. However, depletion of central stores of neurotransmitter amines is responsible for the antipsychotic effects and consequently its adverse side effects such as depression . Reserpine model is based on the ability of antidepressants to reverse the behavioural and biochemical depressive-like syndrome induced by reserpine in rodents [26-29]. In the present investigation, reserpine resulted in significant hypolocomotor activity in the OFT and also a pronounced increase in the immobility duration in the FST as compared with vehicle control. This result is consistent with Qingjun et al.  who reported that reserpine increased floating time in the Porsolt swim test in a dose-dependent and time-dependent manner in rats. Moreover, reserpine was found to induce a syndrome of locomotor hypomotility in the OFT and an increase in the immobility period in the tail suspension test [31-33]. Furthermore, biochemical analysis revealed that chronic reserpine treatment significantly decreased the three neurotransmitters under investigation compared with normal control but had no effect on brain MDA or GSH levels. On the contrary, it induced lipid peroxidation and decreased GSH level in the liver.
Previous investigations revealed that different dose levels of transresveratrol, ranging from 10 to 100 mg/kg, showed antioxidant capability as well as neuroprotective and hepatoprotective effects [11,34-38]. Transresveratrol treatment also reduced immobility time in the FST. However, results obtained from open field are controversial depending on the dose, route and duration of administration, wherein some cases of transresveratrol enhanced locomotor activity in the OFT and in other cases it had no effect on the locomotor activity [39-42]. The present study demonstrated that transresveratrol (60 and 120 mg/kg orally) reversed reserpine-induced depression-like behavioural symptoms in the OFT and FST in a manner comparable to that of fluoxetine; however, it is worth mentioning that the lower dose showed better response. In addition, transresveratrol (60 and 120 mg/kg) reversed the reserpine-induced reduction in the brain's neurotransmitter content. Former studies reported that the effect of transresveratrol on depressive-like behaviours may be partly because of the potentiated activation of monoaminergic system in the brain. Neurochemical assays showed transresveratrol (80 mg/kg) and produced a marked increase of 5-HT levels in the brain's frontal cortex, hippocampus and hypothalamus. Norepinephrine and dopamine levels were also increased in both the frontal cortex and striatum. Furthermore, chronic treatment with transresveratrol was found to inhibit monoamine oxidase-A (MAO)-A activity, particularly in the frontal cortex and hippocampus, whereas MAO-B activity was not affected. These findings indicate that the antidepressant-like effect of transresveratrol involves the regulation of the central serotonin and norepinephrine levels and the related MAO-A activities [43,44].
Fluoxetine has recently been postulated to induce liver damage and mediates free radical reactions owing to its fluorine content [13,45]. However, Zafir and Banu  reported that fluoxetine ameliorated stress-induced oxidative damage. In the present study, fluoxetine ingestion for 20 days normalized liver MDA level and resulted in a significant decrease in serum ALT and AST levels, and significant increase in the GSH level compared with the depressed group. On the contrary, transresveratrol at both dose levels normalized the serum and brain's MDA and GSH levels, as well as ALT and AST contents. It is worth mentioning that the higher dose of transresveratrol showed better hepatoprotective effect than fluoxetine.
| Conclusion|| |
The present study revealed that subchronic ingestion of transresveratrol (60 and 120 mg/kg body weight) for 20 days prevented the depression-like symptoms induced by reserpine. Both the dose levels also showed a hepatoprotective effect. The obtained results were comparable to those of fluoxetine. Further studies are required to investigate the possible mechanism of action as well as safety of using transresveratrol as antidepressant and the exact dose to be used.
| Acknowledgements|| |
The authors thank Jing Tea LLC for providing the Harmoni-T micronized transresveratrol and Novartis Co., Egypt, for providing the reserpine used in the study.
| References|| |
Huang Z, Mao QQ, Zhong XM, Li ZY, Qiu FM, Ip SP. Mechanistic study on the antidepressant-like effect of danggui-shaoyao-san, a chinese herbal formula. Evid Based Complement Alternat Med 2012; 2012:173565.
Devadoss T, Pandey DK, Mahesh R, Yadav SK. Effect of acute and chronic treatment with QCF-3 (4-benzylpiperazin-1-yl) (quinoxalin-2-yl) methanone, a novel 5-HT3 receptor antagonist, in animal models of depression. Pharmacol Rep 2010; 62:245-257.
Mahesh R, Bhatt S, Devadoss T, Jindal A, Gautam B, Pandey D. Antidepressant potential of 5-HT3 receptor antagonist, N-n-propyl-3-ethoxyquinoxaline-2-carboxamide (6n). J Young Pharm 2012; 4:235-244.
Dutta AK, Gopishetty B, Gogoi S, Ali S, Zhen J, Reith M. The novel trisubstituted pyran derivative D-142 has triple monoamine reuptake inhibitory activity and exerts potent antidepressant-like activity in rodents. Eur J Pharmacol 2011; 671:39-44.
Park SW, Kim YK, Lee JG, et al.
Antidepressant-like effects of the traditional Chinese medicine kami-shoyo-san in rats. Psychiatry Clin Neurosci 2007; 61:401-406.
Mao QQ, Ip SP, Kob KM, Tsai SH, Xian YF, Che CT. Effects of peony glycosides on mice exposed to chronic unpredictable stress: further evidence for antidepressant-like activity. J Ethnopharmacol 2009; 124:316-320.
Sun AY, Wang Q, Simonyi A, Sun GY. Trans-resveratrol as a therapeutic agent for neurodegenerative diseases. Mol Neurobiol 2010; 41:375-383.
Amri A, Chaumeil JC, Sfar S, Charrueau C. Administration of trans-resveratrol: what formulation solutions to bioavailability limitations? J Control Release 2012; 158:182-193.
Nakata R, Takahashi S, Inoue H. Recent advances in the study on trans-resveratrol. Biol Pharm Bull 2012; 35:273-279.
Shin SY, Jung SM, Kim MD, Han NS, Seo JH. Production of trans-resveratrol from tyrosine in metabolically engineered Saccharomyces cerevisiae
. Enzyme Microb Technol 2012; 51:211-216
Farghali H, Kutinová Canová N, Lekiæ N. Trans-resveratrol and related compounds as antioxidants with an allosteric mechanism of action in epigenetic drug targets. Physiol Res 2013; 62:1-13.
Kusakawa S, Yamauchi J, Miyamoto Y, Sanbe A, Tanoue A. Estimation of embryotoxic effect of fluoxetine using embryonic stem cell differentiation system. Life Sci 2008; 83:871-877.
Inkielewicz-Stêpniak I. Impact of fluoxetine on liver damage in rats. Pharmacol Rep 2011; 63:441-447.
Guadarrama-Cruz G, Alarcon-Aguilar FJ, Lezama-Velasco R, Vazquez-Palacios G, Bonilla-Jaime H. Antidepressant-like effects of Tagetes lucida
Cav. in the forced swimming test. J Ethnopharmacol 2008; 120:277-281.
Ribas C, Miralles A, Busquets X, García-Sevilla JA. Brain α2 adrenoceptors in monoamine-depleted rats: increased receptor density, G coupling proteins, receptor turnover and receptor mRNA. Br J Pharmacol 2001; 132:1467-1476.
Pruus K, Vaarmann A, Rudissaar R, Allikmets L, Matto V. Role of 5-HT1A receptors in the mediation of acute citalopram effects. A 8-OH-DPAT challenge study. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26:227-232.
Yanpallewar SU, Rai S, Kumar M, Acharya SB. Evaluation of antioxidant and neuroprotective effect of Ocimum sanctum
on transient cerebral ischemia and long-term cerebral hypoperfusion. Pharmacol Biochem Behav 2004; 79:155-164.
Bellés M, Albina ML, Linares V, Gómez M, Sánchez DJ, Domingo JL. Combined action of uranium and stress in the rat: I. Behavioral effects. Toxicol Lett 2005; 158:176-185.
Kim SH, Han J, Seog DH, et al.
Antidepressant effect of Chaihu-Shugan-San extract and its constituents in rat models of depression. Life Sci 2005; 76:1297-1306.
Porsolt RD, Le Pichon M, Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977; 266:730-732.
Pagel P, Blome J, Wolf HU. High-performance liquid chromatographic separation and measurement of various biogenic compounds possibly involved in the pathomechanism of Parkinson's disease. J Chromatogr B Biomed Sci Appl 2000; 746:297-304.
Ruiz-Larea, MB, Leal AM, Liza M, Lacort M, De Groot H. Antioxidant effects of estradiol and 2-hydroxyestradiol on iron-induced lipid peroxidation of rat liver microsomes. Steroids 1994; 59:383-388.
Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys 1959; 82:70-77.
Bulaj G, Kortemme T, Goldenberg D. Ionization-reactivity relationships for cysteine thiols in polypeptides. Biochemistry 1998; 37:8965-8972.
Reitman S, Frankel S. A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. Am J Clin Pathol 1957; 28:56-63.
Kim KW, Kim HD, Jung JS, et al.
Characterization of antidepressant-like effects of p-synephrine stereoisomers. Naunyn Schmiedebergs Arch Pharmacol 2001; 364:21-26.
Minor TR, Huang Q, Foley EA. Cytokine-purine interactions in behavioral depression in rats. Integr Physiol Behav Sci 2003; 38:189-202.
Rojas-Corrales MO, Berrocoso E, Gibert-Rahola J, Micó JA. Antidepressant-like effect of tramadol and its enantiomers in reserpinized mice: comparative study with desipramine, fluvoxamine, venlafaxine and opiates. J Psychopharmacol 2004; 18:404-411.
O'Donnell KC, Gould TD. The behavioral actions of lithium in rodent models: leads to develop novel therapeutics. Neurosci Biobehav Rev 2007; 31:932-962.
Qingjun H, Xinling H, Minor TR. Adenosine A2a receptor mediates reserpine-induced depression in rats. Acta Psychologica Sinica 2003; 35:106-111.
Tadaiesky MT, Andreatini R, Vital MABF. Different effects of 7-nitroindazole in reserpine-induced hypolocomotion in two strains of mice. Eur J Pharmacol 2006; 535:199-207.
Dhingra D, Valecha R. Evaluation of the antidepressant-like activity of convolvulus pluricaulis choisy in the mouse forced swim and tail suspension tests. Med Sci Monit 2007; 13:155-161.
Woode E, Amidu N, Owiredu WKBA, Boakye-Gyasi E, Ansah C, Duwiejua M. Antidepressant-like effects of an ethanolic extract of Sphenocentrum jollyanum
pierre roots in mice. Int J Pharmacol 2009; 5:22-29.
Lu X, Ji C, Xu H, et al.
Trans-resveratrol-loaded polymeric micelles protect cells from A-induced oxidative stress. Int J Pharm 2009; 375:89-96.
Dietrich-Muszalska A, Olas B. Inhibitory effects of polyphenol compounds on lipid peroxidation caused by antipsychotics (haloperidol and amisulpride) in human plasma in vitro. World J Biol Psychiatry 2010; 11:276-281.
Zhang F, Liu J, Shi JS. Anti-inflammatory activities of trans-resveratrol in the brain: role of trans-resveratrol in microglial activation. Eur J Pharmacol 2010; 636:1-7.
Liu Y, Chan F, Sun H, et al.
Trans-resveratrol protects human keratinocytes HaCaT cells from UVA-induced oxidative stress damage by downregulating Keap1 expression. Eur J Pharmacol 2011; 650:130-137.
Ge JF, Peng L, Cheng JQ, et al.
Antidepressant-like effect of trans-resveratrol: involvement of antioxidant effect and peripheral regulation on HPA axis. Pharmacol Biochem Behav 2013; 114-115:64-69.
Xu Y, Wang Z, You W, et al.
Antidepressant-like effect of trans-resveratrol: involvement of serotonin and noradrenaline system. Eur Neuropsychopharmacol 2010; 20:405-413.
Girbovan C, Morin L, Plamondon H. Repeated trans-resveratrol administration confers lasting protection against neuronal damage but induces dose-related alterations of behavioral impairments after global ischemia. Behav Pharmacol 2012; 23:1-13.
Wang Z, Gu J, Wang X, et al.
Antidepressant-like activity of trans-resveratrol treatment in the forced swim test and tail suspension test in mice: the HPA axis, BDNF expression and phosphorylation of ERK. Pharmacol Biochem Behav 2013; 112:104-110.
Bagriyanik HA, Ersoy N, Cetinkaya C, et al.
The effects of trans-resveratrol on chronic constriction injury of sciatic nerve in rats. Neurosci Lett 2014; 561:123-127.
Huang W, Chen Z, Wang Q, et al.
Piperine potentiates the antidepressant-like effect of trans-resveratrol: involvement of monoaminergic system. Metab Brain Dis 2013; 28:585-595.
Yu Y, Wang R, Chen C, et al.
Antidepressant-like effect of trans-resveratrol in chronic stress model: behavioral and neurochemical evidences. J Psychiatr Res 2013; 47:315-322.
Beasley CM Jr, Nilsson ME, Koke SC, Gonzales JS. Efficacy, adverse events, and treatment discontinuations in fluoxetine clinical studies of major depression: a meta-analysis of the 20 mg/day dose. J Clin Psychiatry 2000; 61:722-728.
Zafir A, Banu N. Antioxidant potential of fluoxetine in comparison to Curcuma longa
in restraint-stressed. Eur J Pharmacol 2007; 572:23-31.
[Figure 1], [Figure 2], [Figure 3], [Figure 4]
[Table 1], [Table 2]